ARA-290 · Research brief

ARA-290 for Sale — How to Vet a Peptide Supplier

Real Peptides Research TeamEditorial

Updated September 16, 20269 min read

56 WORDS

Short answer

Two vials labelled ARA-290 can contain measurably different amounts of actual peptide, and both can be honestly labelled. The gap hides in one line on the certificate of analysis that almost nobody reads: net peptide content. We synthesise research peptides in small batches and review assay data on every lot, so this question reaches us constantly.

Key takeaways

ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from helix B of erythropoietin that binds the innate repair receptor, a heteromer of the EPO receptor and CD131, rather than the classical EPO receptor.
Chromatographic purity and net peptide content measure different things, so a vial can report high HPLC purity and still fall short of its labelled milligram weight once counterions and residual water are subtracted.
Every credible listing of ARA-290 for sale should arrive with a lot-matched certificate of analysis containing an HPLC chromatogram and mass spectrometry identity confirmation, not a generic document reused across batches.
Lyophilised peptide is typically stored at -20°C and protected from moisture, while reconstituted solution is generally held at 2 to 8°C and aliquoted to avoid repeated freeze-thaw cycles.
Reported plasma half-life is on the order of minutes, which is why research models are built around receptor-mediated signalling rather than sustained exposure.
Cibinetide reached Phase 2 investigation and has not been approved by the FDA or the EMA, so it is supplied strictly for laboratory research and never for human or veterinary use.

We synthesise research peptides in small batches and review assay data on every lot, so this question reaches us constantly. What separates one listing of ARA-290 for sale from another is rarely the sequence itself. It is the batch documentation, the cold chain, and whether anyone can trace the vial in your hand back to a specific chromatogram.

Where can researchers find ARA-290 for sale, and what should they verify first?

ARA-290 for sale is offered by research peptide suppliers as a lyophilised 11-amino-acid powder, sold strictly for in-vitro and preclinical laboratory use. It is not an approved drug in any jurisdiction. Before buying, verify a batch-specific certificate of analysis showing HPLC purity, mass spectrometry identity confirmation, and net peptide content.

Most buyers assume every listing of ARA-290 for sale delivers an identical product, because the sequence is public and the synthesis is routine chemistry. Purity, identity and content are three separate measurements, and a supplier can pass one while quietly failing another. What follows covers the receptor biology that makes this peptide unlike erythropoietin, the documents worth demanding before money moves, and the storage failures that destroy material without changing how it looks.

What the molecule actually is, and why it is not just EPO

ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from helix B of erythropoietin (EPO), the hormone best known for driving red blood cell production. Its molecular weight sits at roughly 1,257 daltons. That fragment matters because it corresponds to a face of the EPO molecule that does not engage the classical homodimeric EPO receptor, and published work reports no erythropoietic activity as a result. It does not raise haematocrit the way EPO does.

What research from Michael Brines and Anthony Cerami describes it binding instead is the innate repair receptor, a heteromeric complex pairing the EPO receptor with the beta common receptor (CD131). That receptor assembly is expressed on stressed or injured tissue rather than on erythroid precursors, and this selectivity is the entire scientific premise behind the compound.

Cibinetide reached Phase 2 investigation. A trial published in Molecular Medicine in 2013 by Dahan and colleagues examined it in sarcoidosis-associated small fiber neuropathy, using corneal nerve fiber density as an objective endpoint. Research interest has clustered around neuropathic pain and tissue protection models since. It remains investigational, with no approval from the FDA or the EMA.

One property shapes experimental design more than any other. Reported plasma half-life is very short, on the order of minutes, so models generally hinge on receptor-mediated downstream signalling rather than sustained exposure. Anyone weighing ARA-290 for sale against other repair-oriented research peptides should understand that before writing a protocol. Our team answers more questions about that half-life than about anything else in the spec sheet.

The paperwork that separates research material from a mystery vial

Four documents decide whether a vial is usable data or an expensive guess: a lot-matched certificate of analysis, the actual HPLC chromatogram rather than a single summary figure, mass spectrometry confirming the observed mass matches the expected mass for the sequence, and a lot number printed on the vial that matches the certificate header. Miss the fourth and the first three are decorative.

Here is the part nearly every listing glosses over. Chromatographic purity and net peptide content are different numbers measuring different things. Purity describes what fraction of the peptide present is the correct sequence. Net peptide content describes how much of the vial contents is peptide at all, with the balance made up of counterions left from purification, typically acetate or trifluoroacetate, plus residual water. A vial can report high HPLC purity and still sit well below its labelled milligram figure once counterion mass and moisture are subtracted. Two suppliers can both tell the truth and ship materially different quantities of peptide.

That is why we publish batch analytics openly rather than on request, and why researchers cross-checking ARA-290 for sale between vendors can read our certificates of analysis before placing an order. One more question worth asking any supplier: who ran the assay. In-house quality control and independent third-party verification are not the same claim, and vendors who blur the two usually do it deliberately.

Storage, cold chain, and the damage you cannot see

Lyophilised peptide in a sealed vial is the most stable form the compound takes, which is why suppliers ship it that way. Long-term laboratory storage is typically at -20°C, protected from light and moisture, and the powder tolerates short ambient transit because free water content is minimal. Reconstituted solution is a different material: generally refrigerated at 2 to 8°C, aliquoted to avoid repeated freeze-thaw cycles, and treated as having a far shorter usable window.

Moisture, not heat alone, is the primary failure mode. A hygroscopic lyophilised powder that pulls in atmospheric water opens the door to hydrolysis and, in sequences containing asparagine and glutamine residues as this one does, deamidation over time. Visual inspection tells you nothing. A degraded peptide dissolves into a clear solution that looks exactly like an intact one.

In our experience the most common handling error has nothing to do with the freezer. It is opening a cold vial before it has equilibrated to room temperature, which condenses water directly onto the powder the moment the stopper is broken. Letting the vial sit sealed for 20 to 30 minutes first costs nothing and prevents a problem no assay will flag as a handling error.

One line of housekeeping that matters. This is laboratory handling information, not a use protocol: ARA-290 is not approved for human or veterinary administration, and anyone with health questions about neuropathy, nerve injury or tissue repair should talk to their physician or veterinarian rather than a peptide supplier.

ARA-290 for Sale: Sourcing Route Comparison

Not every source of ARA-290 for sale operates to the same analytical standard, and the differences surface in documentation long before they surface in your data. This table compares the four routes researchers realistically choose between.

Sourcing route	Documentation typically provided	Identity and purity risk	Practical cost reality	Bottom line
Dedicated research peptide supplier with per-batch testing	Lot-matched COA with HPLC chromatogram, MS identity confirmation and net peptide content	Lowest, because every claim is falsifiable against one specific lot	Higher per vial than commodity listings, since analytics and cold shipping are real costs	Best fit whenever data integrity matters more than unit price, which covers most bench work
Bulk marketplace or reseller listing	Often a single representative certificate reused across all lots, sometimes nothing at all	High, because the document cannot be tied to the vial that arrives	Cheapest headline price, with failed runs as the unpriced cost	Defensible only for rough preliminary screening, and even then the saving is fragile
Custom synthesis through a contract research organisation	Full analytical package, method documentation and retained samples	Lowest, with the option to specify counterion form and purity thresholds	Highest cost, minimum order quantities and multi-week lead times	The correct route for publication-grade or regulated work, and overkill for routine assays
Wellness or grey-market site selling unlabelled vials	Marketing copy, rarely any analytics	Highest, spanning wrong sequence, unknown content and unrecorded storage history	Mid-range price with no verifiable basis for it	Avoid entirely. A site implying human benefits is advertising that it ignores research-use-only rules

What If: Sourcing and Handling Scenarios

What if the vial arrives warm and the cold pack has fully melted?

Log the arrival condition and contact the supplier before opening anything. Lyophilised peptide is comparatively robust in transit precisely because free water content is minimal, and brief ambient excursions during shipping are normal for powder form. The real concern is repeated temperature cycling or a compromised stopper seal, since moisture ingress rather than heat alone drives hydrolysis and deamidation. A supplier that tracks lot numbers can tell you when that batch shipped and what the retained sample shows on re-assay, which is a far better answer than guesswork.

What if the powder looks like a thin film, or the vial appears empty?

Do not assume you have been short-changed. Lyophilising a few milligrams of peptide frequently leaves a barely visible film on the vial wall or base rather than a fluffy cake, and cake appearance varies with fill volume, freezing rate and formulation. Weight is confirmed by the certificate, not by eye. A collapsed or melted-looking cake is a genuinely different signal: that pattern suggests the material passed above its glass transition temperature at some point, and it is worth raising with the supplier before use.

What if the batch number on the certificate does not match the vial?

Stop and request the matching document before doing anything else. A certificate of analysis carries meaning only when its lot number corresponds to the physical vial in front of you, because purity and content are batch properties rather than product properties. Some vendors publish one representative certificate and reuse it indefinitely, which converts a quality document into marketing material. Any listing of ARA-290 for sale that cannot produce lot-matched analytics on request should be treated as unverified material and handled accordingly.

The Blunt Truth About Buying Investigational Peptides

Here is the honest answer: the molecule is the commodity, and the documentation is the actual product. ARA-290 has never been approved by the FDA or any comparable regulator, development as cibinetide stopped at Phase 2, and no supplier anywhere can lawfully sell it for human or veterinary use. Any listing of ARA-290 for sale that gestures at outcomes, benefits or protocols is telling you something genuinely useful, just not what it intended. A vendor that ignores the rules governing its own category rarely applies more discipline to its analytics.

Researchers comparing ARA-290 for sale across suppliers can review the compound page and its batch analytics directly. Our ARA-290 listing sits alongside detailed ARA-290 research FAQs, published batch certificates, and the wider research peptide catalogue covering compounds such as BPC-157 and TB-500 used in tissue-repair models. Fulfilment and shipping details live on our locations page.

ARA-290 for sale is, functionally, a documentation purchase wearing a vial. The chemistry has been routine for years, so what varies between vendors is whether anyone can prove which molecule is in the bottle, at what content, from which synthesis run. Researchers who build that verification into procurement instead of discovering it while troubleshooting a failed assay protect the only resource a study cannot replace, which is the time between hypothesis and clean data. Read the chromatogram before you read the price.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Ask for a lot-matched certificate of analysis showing the HPLC chromatogram, mass spectrometry identity confirmation and net peptide content, then confirm the lot number on the document matches the number printed on the vial. Also ask who performed the assay, since in-house quality control and independent third-party verification are different claims. Storage and shipping conditions should be stated, not implied.

ARA-290 is supplied as a research chemical for in-vitro and preclinical laboratory use, and it is not an approved drug in the United States or the European Union. It has not been authorised by the FDA or the EMA for human or veterinary administration. Suppliers may lawfully sell it as research material, but any vendor marketing it for personal use is operating outside research-use-only rules.

Most of the spread comes from analytics, batch size and cold shipping rather than from the peptide itself. Per-batch HPLC and mass spectrometry testing, retained samples and temperature-controlled fulfilment all carry real cost, and suppliers who skip them can list lower. Net peptide content is the other hidden variable, because a cheaper vial may simply contain less actual peptide per labelled milligram.

ARA-290 is an 11-amino-acid fragment derived from helix B of erythropoietin, and published work reports that it does not engage the classical homodimeric EPO receptor. It instead binds the innate repair receptor, a heteromer of the EPO receptor and the beta common receptor CD131. The practical consequence in research models is that it shows no erythropoietic activity, so it does not raise haematocrit the way full-length EPO does.

Net peptide content states what percentage of the vial contents is peptide, with the remainder consisting of counterions left over from purification, usually acetate or trifluoroacetate, plus residual water. It is not the same measurement as HPLC purity, which only describes what fraction of the peptide present is the correct sequence. A vial can show high purity and still deliver less peptide mass than its label weight suggests.

Lyophilised peptide is typically held at -20°C for long-term storage, sealed, protected from light and kept away from moisture. Reconstituted solution is generally refrigerated at 2 to 8°C and aliquoted so the material is not subjected to repeated freeze-thaw cycles. Vials should be allowed to reach room temperature while still sealed before opening, otherwise atmospheric moisture condenses directly onto the powder.

No. ARA-290 is sold strictly as research-use-only material and is not approved for human or veterinary administration by any regulator. Suppliers cannot provide dosing, timing or administration guidance, and no legitimate vendor will. Anyone with questions about nerve injury, neuropathy or tissue repair in a person or an animal should talk to their physician or veterinarian.

There is no FDA-approved ARA-290 product. Development under the name cibinetide reached Phase 2 investigation, including a trial published in Molecular Medicine in 2013 examining sarcoidosis-associated small fiber neuropathy with corneal nerve fiber density as an endpoint, but the compound has not been approved. Because no approved reference product exists, compounding pharmacies have no approved formulation to compound from.

Once a lyophilised peptide is reconstituted it becomes far less stable than the dry powder, and usable life depends on the diluent, storage temperature, pH and how often the vial is disturbed. Refrigerated storage at 2 to 8°C with single-use aliquots is standard laboratory practice to limit freeze-thaw degradation. Degradation is not visible, so solutions held beyond a supplier's stated window should be treated as analytically unreliable rather than assumed intact.

Usually not. Lyophilising a small quantity of peptide often produces a thin film on the vial wall or base rather than a visible cake, and appearance varies with fill volume and freezing conditions. Contents are verified by the certificate of analysis, not by visual inspection. A collapsed or glassy, melted-looking cake is a different matter and suggests a temperature excursion worth reporting to the supplier.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA